{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T08:19:07Z","timestamp":1788941947238,"version":"build-2803163510"},"reference-count":57,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2019.7850","type":"journal-article","created":{"date-parts":[[2019,7,26]],"date-time":"2019-07-26T11:30:49Z","timestamp":1564140649000},"page":"e197850","source":"Crossref","is-referenced-by-count":41,"title":["Antipsychotic Treatment Among Youths With Attention-Deficit\/Hyperactivity Disorder"],"prefix":"10.1001","volume":"2","author":[{"given":"Ryan S.","family":"Sultan","sequence":"first","affiliation":[{"name":"Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York, New York"},{"name":"New York State Psychiatric Institute, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York, New York"},{"name":"New York State Psychiatric Institute, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Crystal","sequence":"additional","affiliation":[{"name":"Institute for Health, Health Care Policy, and Aging Research, Rutgers University, New Brunswick, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Olfson","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York, New York"},{"name":"New York State Psychiatric Institute, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2019,7,26]]},"reference":[{"issue":"1","key":"zoi190313r1","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1001\/jamapsychiatry.2013.3074","article-title":"National trends in the mental health care of children, adolescents, and adults by office-based physicians.","volume":"71","author":"Olfson","year":"2014","journal-title":"JAMA Psychiatry"},{"issue":"9","key":"zoi190313r2","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1001\/jamapsychiatry.2015.0500","article-title":"Treatment of young people with antipsychotic medications in the United States.","volume":"72","author":"Olfson","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"12","key":"zoi190313r3","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1001\/archgenpsychiatry.2012.647","article-title":"National trends in the office-based treatment of children, adolescents, and adults with antipsychotics.","volume":"69","author":"Olfson","year":"2012","journal-title":"Arch Gen Psychiatry"},{"issue":"19","key":"zoi190313r4","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1001\/jama.2018.5690","article-title":"Trends in prescription medication use among children and adolescents\u2014United States, 1999-2014.","volume":"319","author":"Hales","year":"2018","journal-title":"JAMA"},{"issue":"11","key":"zoi190313r5","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1097\/CHI.0b013e3181b76658","article-title":"A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder.","volume":"48","author":"Marcus","year":"2009","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"5","key":"zoi190313r6","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1056\/NEJMoa013171","article-title":"Risperidone in children with autism and serious behavioral problems.","volume":"347","author":"McCracken","year":"2002","journal-title":"N Engl J Med"},{"issue":"11","key":"zoi190313r7","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1176\/appi.ajp.2008.07061035","article-title":"A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia.","volume":"165","author":"Findling","year":"2008","journal-title":"Am J Psychiatry"},{"issue":"10","key":"zoi190313r8","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1176\/appi.ajp.2007.06111932","article-title":"Olanzapine versus placebo in the treatment of adolescents with bipolar mania.","volume":"164","author":"Tohen","year":"2007","journal-title":"Am J Psychiatry"},{"issue":"10","key":"zoi190313r9","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.4088\/JCP.09m05164yel","article-title":"Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study.","volume":"70","author":"Findling","year":"2009","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"zoi190313r10","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/pds.v20.2","article-title":"Increasing off-label use of antipsychotic medications in the United States, 1995-2008.","volume":"20","author":"Alexander","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"zoi190313r11","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1111\/hesr.2012.47.issue-5","article-title":"The relationship between mental health diagnosis and treatment with second-generation antipsychotics over time: a national study of US Medicaid-enrolled children.","volume":"47","author":"Matone","year":"2012","journal-title":"Health Serv Res"},{"issue":"2","key":"zoi190313r12","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.molmed.2010.10.010","article-title":"Antipsychotic drugs and obesity.","volume":"17","author":"Correll","year":"2011","journal-title":"Trends Mol Med"},{"issue":"2","key":"zoi190313r13","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1517\/14740338.2015.979150","article-title":"Do antipsychotics increase diabetes risk in children and adolescents?","volume":"14","author":"Galling","year":"2015","journal-title":"Expert Opin Drug Saf"},{"issue":"2","key":"zoi190313r14","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1001\/jamapsychiatry.2018.3421","article-title":"Association of antipsychotic treatment with risk of unexpected death among children and youths.","volume":"76","author":"Ray","year":"2019","journal-title":"JAMA Psychiatry"},{"issue":"9","key":"zoi190313r15","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1001\/jama.2015.0763","article-title":"Medicaid prior authorization policies for pediatric use of antipsychotic medications.","volume":"313","author":"Schmid","year":"2015","journal-title":"JAMA"},{"issue":"10","key":"zoi190313r16","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1176\/appi.ps.201600489","article-title":"Second-generation antipsychotic prescribing patterns for pediatric patients enrolled in West Virginia Medicaid.","volume":"68","author":"Melvin","year":"2017","journal-title":"Psychiatr Serv"},{"issue":"1","key":"zoi190313r17","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1001\/jamapsychiatry.2017.3493","article-title":"Pediatric use of antipsychotic medications before and after Medicaid peer review implementation.","volume":"75","author":"Zito","year":"2018","journal-title":"JAMA Psychiatry"},{"issue":"3","key":"zoi190313r18","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1089\/cap.2017.0077","article-title":"National patterns of commonly prescribed psychotropic medications to young people.","volume":"28","author":"Sultan","year":"2018","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"2","key":"zoi190313r19","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1176\/ps.2010.61.2.123","article-title":"Evidence-based use of second-generation antipsychotics in a state Medicaid pediatric population, 2001-2005.","volume":"61","author":"Pathak","year":"2010","journal-title":"Psychiatr Serv"},{"issue":"10","key":"zoi190313r20","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1089\/cap.2018.0068","article-title":"Aripiprazole\/methylphenidate combination in children and adolescents with disruptive mood dysregulation disorder and attention-deficit\/hyperactivity disorder: an open-label study.","volume":"28","author":"Pan","year":"2018","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"1","key":"zoi190313r21","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1089\/cap.2015.0167","article-title":"Pharmacotherapy of aggression in child and adolescent psychiatric disorders.","volume":"26","author":"Gurnani","year":"2016","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"2","key":"zoi190313r22","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1177\/070674371506000203","article-title":"The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: a systematic review and meta-analysis\u2014part 2: antipsychotics and traditional mood stabilizers.","volume":"60","author":"Pringsheim","year":"2015","journal-title":"Can J Psychiatry"},{"issue":"5","key":"zoi190313r24","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1097\/chi.0b013e3180323354","article-title":"Risperidone augmentation for treatment-resistant aggression in attention-deficit\/hyperactivity disorder: a placebo-controlled pilot study.","volume":"46","author":"Armenteros","year":"2007","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"4","key":"zoi190313r25","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1089\/cap.2007.0124","article-title":"Aripiprazole in children with attention-deficit\/hyperactivity disorder.","volume":"18","author":"Findling","year":"2008","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"5","key":"zoi190313r26","doi-asserted-by":"publisher","first-page":"756","DOI":"10.4088\/JCP.08m04726","article-title":"Aripiprazole in children and adolescents with bipolar disorder comorbid with attention-deficit\/hyperactivity disorder: a pilot randomized clinical trial.","volume":"70","author":"Tramontina","year":"2009","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"zoi190313r27","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1089\/cap.2006.0012","article-title":"Quetiapine addition in methylphenidate treatment-resistant adolescents with comorbid ADHD, conduct\/oppositional-defiant disorder, and aggression: a prospective, open-label study.","volume":"17","author":"Kronenberger","year":"2007","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"7","key":"zoi190313r29","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1177\/1087054714548035","article-title":"Drug holidays from ADHD medication: international experience over the past four decades.","volume":"19","author":"Ibrahim","year":"2015","journal-title":"J Atten Disord"},{"issue":"9","key":"zoi190313r30","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1001\/archpedi.161.9.857","article-title":"Prevalence, recognition, and treatment of attention-deficit\/hyperactivity disorder in a national sample of US children.","volume":"161","author":"Froehlich","year":"2007","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"6","key":"zoi190313r31","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1176\/appi.ajp.160.6.1071","article-title":"National trends in the treatment of attention deficit hyperactivity disorder.","volume":"160","author":"Olfson","year":"2003","journal-title":"Am J Psychiatry"},{"issue":"9","key":"zoi190313r32","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.euroneuro.2009.04.008","article-title":"Antipsychotics in children and adolescents: increasing use, evidence for efficacy and safety concerns.","volume":"19","author":"Vitiello","year":"2009","journal-title":"Eur Neuropsychopharmacol"},{"issue":"1","key":"zoi190313r33","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1097\/chi.0b013e31815b5cb1","article-title":"Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes.","volume":"47","author":"Correll","year":"2008","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"4","key":"zoi190313r35","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1037\/0033-295X.100.4.674","article-title":"Adolescence-limited and life-course-persistent antisocial behavior: a developmental taxonomy.","volume":"100","author":"Moffitt","year":"1993","journal-title":"Psychol Rev"},{"issue":"6","key":"zoi190313r36","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1037\/a0015862","article-title":"Trajectories of antisocial behavior and psychosocial maturity from adolescence to young adulthood.","volume":"45","author":"Monahan","year":"2009","journal-title":"Dev Psychol"},{"issue":"1","key":"zoi190313r37","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.dr.2007.08.002","article-title":"A social neuroscience perspective on adolescent risk-taking.","volume":"28","author":"Steinberg","year":"2008","journal-title":"Dev Rev"},{"issue":"3","key":"zoi190313r38","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1023\/A:1019711113312","article-title":"Effects of school-based mental health programs on mental health service use by adolescents at school and in the community.","volume":"4","author":"Slade","year":"2002","journal-title":"Ment Health Serv Res"},{"issue":"8","key":"zoi190313r39","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1017\/S0033291713002419","article-title":"The effects of temporally secondary co-morbid mental disorders on the associations of DSM-IV ADHD with adverse outcomes in the US National Comorbidity Survey Replication Adolescent Supplement (NCS-A).","volume":"44","author":"Kessler","year":"2014","journal-title":"Psychol Med"},{"issue":"4","key":"zoi190313r40","doi-asserted-by":"publisher","first-page":"e796","DOI":"10.1542\/peds.2010-0086","article-title":"Stimulant-responsive and stimulant-refractory aggressive behavior among children with ADHD.","volume":"126","author":"Blader","year":"2010","journal-title":"Pediatrics"},{"issue":"1","key":"zoi190313r41","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1097\/DBP.0000000000000359","article-title":"Impact of mental health comorbidities on the community-based pediatric treatment and outcomes of children with attention deficit hyperactivity disorder.","volume":"38","author":"Al Ghriwati","year":"2017","journal-title":"J Dev Behav Pediatr"},{"issue":"7","key":"zoi190313r42","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.4088\/JCP.v68n0713","article-title":"Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study.","volume":"68","author":"Souery","year":"2007","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"zoi190313r43","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1176\/appi.ajp.160.4.757","article-title":"Psychiatric inpatient, outpatient, and medication utilization and costs among privately insured youths, 1997-2000.","volume":"160","author":"Martin","year":"2003","journal-title":"Am J Psychiatry"},{"issue":"1","key":"zoi190313r44","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/1753-2000-8-27","article-title":"Risk factors for rehospitalization and inpatient care among pediatric psychiatric intake response center patients.","volume":"8","author":"Tossone","year":"2014","journal-title":"Child Adolesc Psychiatry Ment Health"},{"issue":"11","key":"zoi190313r45","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1097\/01.chi.0000235077.32661.61","article-title":"Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD.","volume":"45","author":"Greenhill","year":"2006","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"7","key":"zoi190313r46","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.jaac.2015.04.004","article-title":"Pharmacotherapy of the Preschool ADHD Treatment Study (PATS) children growing up.","volume":"54","author":"Vitiello","year":"2015","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"9","key":"zoi190313r47","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1037\/ccp0000230","article-title":"Remotely delivering real-time parent training to the home: an initial randomized trial of Internet-delivered parent-child interaction therapy (I-PCIT).","volume":"85","author":"Comer","year":"2017","journal-title":"J Consult Clin Psychol"},{"issue":"6","key":"zoi190313r48","doi-asserted-by":"publisher","first-page":"e1577","DOI":"10.1542\/peds.2010-1361","article-title":"Treatment of maladaptive aggression in youth: CERT guidelines II\u2014treatments and ongoing management.","volume":"129","author":"Scotto Rosato","year":"2012","journal-title":"Pediatrics"},{"issue":"3","key":"zoi190313r49","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1097\/00004583-200203000-00004","article-title":"Psychopharmacology and aggression\u2014I: a meta-analysis of stimulant effects on overt\/covert aggression-related behaviors in ADHD.","volume":"41","author":"Connor","year":"2002","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"3","key":"zoi190313r50","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1097\/chi.0b013e31802f1454","article-title":"Consensus report on impulsive aggression as a symptom across diagnostic categories in child psychiatry: implications for medication studies.","volume":"46","author":"Jensen","year":"2007","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"5","key":"zoi190313r51","doi-asserted-by":"publisher","first-page":"w770","DOI":"10.1377\/hlthaff.28.5.w770","article-title":"Broadened use of atypical antipsychotics: safety, effectiveness, and policy challenges.","volume":"28","author":"Crystal","year":"2009","journal-title":"Health Aff (Millwood)"},{"issue":"8","key":"zoi190313r52","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s00127-008-0339-8","article-title":"Descriptive epidemiology of intimate partner aggression in Ukraine.","volume":"43","author":"O\u2019Leary","year":"2008","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"issue":"2","key":"zoi190313r53","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1089\/cap.2009.0076","article-title":"Impulsive aggression in attention-deficit\/hyperactivity disorder: symptom severity, co-morbidity, and attention-deficit\/hyperactivity disorder subtype.","volume":"20","author":"Connor","year":"2010","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"16","key":"zoi190313r54","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.1056\/NEJMp1103168","article-title":"Our flawed but beneficial Medicaid program.","volume":"364","author":"Frakt","year":"2011","journal-title":"N Engl J Med"},{"issue":"2","key":"zoi190313r55","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1542\/peds.2006-0162","article-title":"Increased rates of morbidity, mortality, and charges for hospitalized children with public or no health insurance as compared with children with private insurance in Colorado and the United States.","volume":"118","author":"Todd","year":"2006","journal-title":"Pediatrics"},{"issue":"10","key":"zoi190313r56","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1001\/jamapsychiatry.2013.2053","article-title":"Antipsychotics and the risk of type 2 diabetes mellitus in children and youth.","volume":"70","author":"Bobo","year":"2013","journal-title":"JAMA Psychiatry"},{"issue":"6","key":"zoi190313r57","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1377\/hlthaff.2016.0064","article-title":"Rapid growth of antipsychotic prescriptions for children who are publicly insured has ceased, but concerns remain.","volume":"35","author":"Crystal","year":"2016","journal-title":"Health Aff (Millwood)"},{"key":"zoi190313r23","unstructured":"FindlingRL, DrurySS, JensenPS. AACAP Committee on Quality Issues. Practice parameter for the use of atypical antipsychotic medications in children and adolescents. https:\/\/www.aacap.org\/App_Themes\/AACAP\/docs\/practice_parameters\/Atypical_Antipsychotic_Medications_Web.pdf. Published 2011. Accessed June 18, 2019."},{"key":"zoi190313r28","unstructured":"Leigh HansenMSM. The Truven Health MarketScan Databases for life sciences researchers. https:\/\/truvenhealth.com\/Portals\/0\/Assets\/2017-MarketScan-Databases-Life-Sciences-Researchers-WP.pdf. Published March 2017. Accessed February 12, 2018."},{"key":"zoi190313r34","unstructured":"Choosing Wisely. American Psychiatric Association. http:\/\/www.choosingwisely.org\/clinician-lists\/american-psychiatric-association-antipsychotics-in-children-or-adolescents\/. Updated August 21, 2014. Accessed June 1, 2019."}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/article-pdf\/2\/7\/e197850\/17820308\/sultan_2019_oi_190313.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T13:32:24Z","timestamp":1566999144000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2739046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,26]]},"references-count":57,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.7850","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,26]]}}}